Glycolysis-centered understanding of ovarian cancer may support biomarker-guided combination strategies and improve translational therapeutic design
This narrative review addresses the topic of glycolysis-centered understanding of ovarian cancer. The authors synthesize arguments suggesting that this perspective may support biomarker-guided combination strategies and improve translational therapeutic design. The scope covers potential pathways for future research rather than reporting specific trial data or patient outcomes.
The review highlights several key limitations that affect the certainty of these conclusions. These include metabolic heterogeneity, compensatory pathway activation, limited biomarkers, and insufficient clinical validation. These factors suggest that current evidence is not yet robust enough to drive widespread clinical adoption of specific glycolysis-targeted interventions.
Regarding safety, adverse events, serious adverse events, discontinuations, and tolerability were not reported in this source. The review does not provide specific numerical data on efficacy or safety profiles for any medication.
The practice relevance is that a glycolysis-centered understanding of ovarian cancer may support biomarker-guided combination strategies and improve translational therapeutic design. Clinicians should interpret these findings as conceptual guidance rather than established treatment protocols, given the noted gaps in clinical validation.